Comparative Pharmacology
Head-to-head clinical analysis: LIBRELEASE versus VALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRELEASE versus VALIUM.
LIBRELEASE vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIBRELEASE is a novel therapeutic agent that modulates neurotransmitter release by binding to presynaptic voltage-gated calcium channels, specifically the alpha-2-delta subunit, thereby reducing calcium influx and subsequent neurotransmitter exocytosis. This results in decreased neuronal excitability and modulation of pain pathways.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
10 mg once daily, oral, administered in the morning.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
Terminal elimination half-life 12–15 hours in healthy adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Primarily renal excretion of unchanged drug (60–70%) and hepatic metabolism with biliary/fecal elimination (20–30%).
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine